Esophageal squamous cell carcinoma (ESCC) is among the most common malignancies, but little is known about its spatial intratumoral heterogeneity (ITH) and temporal clonal evolutionary processes. To address this, we performed multiregion whole-exome sequencing on 51 tumor regions from 13 ESCC cases and multiregion global methylation profiling for 3 of these 13 cases. We found an average of 35.8% heterogeneous somatic mutations with strong evidence of ITH. Half of the driver mutations located on the branches of tumor phylogenetic trees targeted oncogenes, including PIK3CA, NFE2L2 and MTOR, among others. By contrast, the majority of truncal and clonal driver mutations occurred in tumor-suppressor genes, including TP53, KMT2D and ZNF750, among others. Interestingly, phyloepigenetic trees robustly recapitulated the topological structures of the phylogenetic trees, indicating a possible relationship between genetic and epigenetic alterations. Our integrated investigations of spatial ITH and clonal evolution provide an important molecular foundation for enhanced understanding of tumorigenesis and progression in ESCC.
Esophageal carcinoma is among the most common human cancers, causing over 400,000 deaths worldwide annually 1, 2 . The areas with highest risk are located in eastern Asia, as well as eastern and southern Africa, and the most prevalent type is ESCC 1,2 . The 5-year survival rates for patients with ESCC undergoing surgery are below 30% because a large proportion of tumors are unresectable or have already metastasized before diagnosis 3 .
Recently, several large-scale genomic studies have characterized ESCC genomes as having hundreds of somatic mutations and copy number alterations (CNAs) and have identified significantly mutated genes, including TP53, PIK3CA and ZNF750, among others [4] [5] [6] [7] [8] [9] . The APOBEC signature is a predominant mutational spectrum and contributes to the mutagenic processes of ESCCs 6, 8 . However, the genomic alterations identified in all of these studies were obtained using only single samples representing individual cases, and little is known about the spatial ITH and temporal clonal evolutionary processes of the mutational spectrum in ESCC. Moreover, although alterations in DNA methylation have been observed in ESCC, the degree of ITH for these epigenetic changes is still unknown, and whether such heterogeneity correlates with genetic architecture remains unexplored.
Precise understanding of both the genomic and epigenomic architectures of primary ESCC tumors is crucial for the development of personalized patient treatment and molecular-based biomarkers 10 . Furthermore, an integrated investigation of the genomic and epigenomic evolutionary trajectories of ESCC may also provide new insights into the relationship between the genome and epigenome. In the present study, we address these critical issues through integrative molecular approaches, including multiregion whole-exome sequencing (M-WES) and global methylation profiling, as well as phylogenetic and phyloepigenetic tree construction.
RESULTS

Spatial ITH of ESCC
M-WES was performed on genomic DNA from 13 patients with primary ESCC; the clinicopathological parameters of these patients are listed in Supplementary Table 1 . In total, 51 tumor regions and 13 matched morphologically normal esophageal tissue samples (4 tumor regions and 1 matched normal tissue sample per case, with the exception of ESCC04, for which samples were obtained from only 3 tumor regions) were sequenced, with a mean coverage depth of 150×. A total of 1,610 non-silent somatic mutations (affecting 1,427 genes) and Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma 568 silent mutations were identified, with a validation rate of 90% ( Supplementary Tables 2 and 3) .
To explore ITH and the genomic evolution of ESCC, phylogenetic trees were constructed on the basis of somatic mutations (both silent and non-silent) identified in each tumor region. The trunk, 'shared' branches and 'private' branches of each tree represent mutations in all tumor regions, in some but not all tumor regions, and in only one tumor region, respectively. The phylogenetic trees varied extensively among the different cases ( Fig. 1a and Supplementary Fig. 1) , and all 13 of the ESCCs showed evidence of spatial ITH, with an average of 35.8% (780/2,178; range, 8.0-60.9%) of somatic variants having spatial heterogeneity.
Characterization of the relative timing of mutations affecting driver genes with possible biological relevance is essential for identifying the evolutionary processes of the cancer genome, as well as for further improving precision medicine strategies. To address this, we identified potential driver mutations according to recent large-scale ESCC sequencing data [4] [5] [6] [7] [8] , the Catalog of Somatic Mutations in Cancer (COSMIC) cancer gene census 11 and pan-cancer analysis 12 ; these mutations were then traced within the phylogenetic trees (Online Methods). Overall, driver mutations were significantly more enriched in trunks than passenger mutations were (77.8% versus 63.8%; P = 0.023; Fig. 1b ). This indicates that driver mutations are relatively early events during the evolutionary process of the tumors, in accordance with previous findings in other tumor types 13 . We next separated putative driver mutations into those occurring in oncogenes or tumor-suppressor genes (TSGs). Notably, half of the driver mutations (50.0%) that mapped to branches were in oncogenes, including PIK3CA, KIT, NFE2L2, MTOR and FAM135B. In comparison, only 22.4% of the driver mutations located on trunks affected oncogenes, and the rest were in TSGs. For example, TP53 mutations were present in 12 of the 13 cases and were truncal in all of the mutated cases, in agreement with recent reports 14, 15 . It is worthwhile to note that potentially actionable mutations, such as those targeting PIK3CA and MTOR, tended to be oncogenic branch events. These findings highlight the additional caution needed when considering the inhibition of these mutants in ESCC, given previous studies showing that the suppression of subclonal drivers leads to growth acceleration for non-mutated subpopulations 16 .   T1   T1   T1   T1   T1   T2   T2   T2   T2   T2   T3   T3   T3   T3   WAS   SDHD   TP53   CBL  PTPRC  KMT2D   TP53   BRCA2   NFE2L2   TP53   TP53   TP53   KEAP1   SUZ12  TP53  TP53   NOTCH2  COL2A1  TRAF7  CREBBP  PAX8  FAM135B  FAT2   ATM   TP53   ZNF750   CD79A  FAT1  KMT2D   TP53   ERCC3   MTOR  PIK3CA   AFF4  FAM135B   KMT2A   TP53   TP53   RASA1  KMT2D  TP53   NFE2L2   NOTCH1  NUP214   LIFR  POLE  ZNF750  PRDM1   UBR5   FAT1  HIST1H4E   BMPR1A  FAM46C   TSC1   ASXL1  MSN   PTPRB   ERG  RUNX1   T3   T4   T4   T1   T2  T4   T1   T2   T3  T4   T1   T2  T3  T4   T1   T2 T3  T4   T4  T1   T1   T1  T1  T2  T2  T2  T2  T3  T3  T3   T3   TP53BP1  KIT   ATR  BRIP1   T4  T4   T4   T4   T4   T4   T1  T2  T3  T4  T1  T2  T3  T4  T1  T2  T3  T4   T1  T2  T3  T4   T1  T2  T3  T4   T1  T2  T3  T4   T1  T2  T3  T4   T1  T2  T3  T4   T1  T2  T3  T4   T1  T2  T3  T4   T1  T2  T3  T4   T1  T2  T3  T4   T1  T2  T4   ESCC01  (n = 241 Heat maps show the presence (blue) or absence (gray) of a somatic mutation in each tumor region (T). Each gene is arranged in a row, and cancerrelated genes with putative driver mutations are indicated. The total number of mutations (n) and proportion of branched mutations in each case are provided above each tree. (b) Bar plots show the proportions of putative driver mutations versus other mutations on the trunks and branches. Statistical differences of truncal and branched proportions, between driver and other mutations across all cases, were analyzed using a χ 2 test, and a significant P value is shown. 1 5 0 2 VOLUME 48 | NUMBER 12 | DECEMBER 2016 Nature GeNetics A r t i c l e s Clonal status of putative driver mutations We next investigated the clonal status of somatic mutations within individual regions. The cancer cell fraction (CCF) for each tumor region was calculated as described previously through integrative analysis of local copy number, variant allele frequency (VAF) and tumor cell purity 16, 17 . Several driver mutations were subclonal and possibly occurred as late events in ESCC, including mutations in MTOR, KEAP1, PTPRB and FAM135B. In contrast, cancer-related genes on the trunks, such as TP53, NOTCH1, CREBBP, KMT2D and ZNF750, were predominantly mutated in a fully clonal manner ( Fig. 2) , further verifying our earlier phylogenetic tree analysis showing that these mutations were possibly early lesions during ESCC development. Of note, a number of driver variants detected as clonal within some individual tumor regions were absent in others from the same individual, producing an 'illusion' of clonal dominance. For example, a PIK3CA hotspot mutation (p.Met1043Ile) was undetectable in tumor regions T2 and T3 in case ESCC13 but was clonally dominant in the other two regions. Likewise, a hotspot mutation in the KIT gene (p.Glu601Lys) was present in 100% of tumor cells from regions T1 and T3 in case ESCC08, yet was absent in the rest of the tumor regions. Such clonal dominance was also observed for mutations in NFE2L2 in case ESCC12. Our results suggest that driver mutations can have mixed and complex intratumoral clonal status in ESCC and that the current single-sampling approach may misinter-pret these critical genomic lesions because of the illusion of clonal dominance. We further investigated all non-silent variants in genes and related pathways that could potentially be targeted therapeutically. Mutations affecting components of the phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) pathway (KIT, AURKA and CCND2) were always late events (branched/subclonal) ( Supplementary Fig. 2) . By contrast, variants in ERBB4, FGFR2, BRCA2, ATM and TP53 were mutated as early events (truncal/clonal), suggesting their potential as candidate actionable targets for ESCC.
ITH of copy number alterations
We next analyzed ITH at the copy number level ( Supplementary  Table 4 ). First, recurrent CNAs that involve important cancer-related genes in ESCC were identified on the basis of our previous results 6 , and we confirmed that the present cohort harbored these recurrent CNAs at similar frequencies ( Supplementary Fig. 3 ). Although CNAs were generally more similar within cases than between different cases, we found extensive ITH for CNAs, with 90% (9/10) of all recurrent CNAs being spatially heterogeneous. For example, in ESCC08, amplification of chromosome 7p11.2 (encompassing EGFR) was observed in regions T1 and T4, but not in regions T2 and T3. Similarly, deletions of chromosome 9p21.3 (harboring CDKN2A and CDKN2B) were ubiquitous in some cases but also occurred as heterogeneous aberrations in other samples. The only driver CNA Cancer genes ESCC01
NA NA 0 CCF 0.5 T1 T2 T3 T4 T1 T2 T3 T4 T1 T2  T2  T1  T3 T4  T4 T1 T2 T3 T4 T1 T2 T3 T4 T1 T2 T3 T4 T1 T2 T3 T4 T1 T2 T3 T4 T1 T2 T3 T4 T1 T2 T3 T4 T1 T2 T3 T4 T1 T2 found to be consistently ubiquitous was copy number gain of 11q13, which encompasses a number of oncogenes, including CCND1, ANO1 (refs. [18] [19] [20] and CTTN 21, 22 , highlighting the importance of this aberration as a founder genomic lesion in the development of ESCC. These results suggest that, similar to somatic mutations, CNAs also show notable spatial ITH, concordant with observations in several other types of cancer [23] [24] [25] . The within-patient mutational rate (mean = 168 mutations per case) was higher than the within-region mutational rate (mean = 139 mutations per region; Supplementary Table 5 ), highlighting the improved resolution of our multiple-biopsy approach for genomic interrogation. In particular, in the case of cancer-related genes on branches, the current M-WES approach markedly increased the sensitivity of the detection rate ( Table 1) . For example, ATR and TSC1 mutations, which were detected in only 2% of tumor regions (in agreement with previous results), occurred in 7.7% of cases. In addition, the proportion of subclonal mutations detected in each tumor region was much lower than that in each case ( Table 2 and Supplementary Fig. 4) . These results again signify that the analysis of sequencing data obtained from a single biopsy will likely underestimate the prevalence of mutations, especially for those acquired late in the mutational process 24 .
Temporal dissection of mutational spectra and signatures
To determine the temporal dynamics of the mutagenic processes in ESCC, the mutational spectra of mutations on both trunks and branches were analyzed using deconstructSigs 26 , which identifies the linear combination of predefined signatures that most accurately reconstructs the mutational profile of a single tumor sample. The overall mutational spectra were similar for trunk and branch mutations, with very strong enrichment of signature 1 substitutions (associated with age) and more subtle but enriched representation of APOBECassociated signatures 2 and 13 substitutions (C>G and C>T substitutions in a TCW context, where W = A, G, C or T) ( Fig. 3a) . We next calculated the contributions of individual mutational signatures to each tumor ( Fig. 3b ) and identified several signatures within the tumors tested, including signature 1 (age), signatures 2 and 13 (APOBEC), and signatures 6 and 15 (DNA mismatch repair), in agreement with previous results in esophageal squamous and other squamous-type cancers 6, 8, 27 . Interestingly, we noticed that a number of tumors displayed a prominent decrease in the relative contribution of signature 1 in branch as compared to trunk mutations, although this decrease did not reach statistical significance owing to the relatively small number of tumors analyzed. In some of these cases, we also observed an increase in the contribution of signatures associated with DNA damage (including signatures 3 and 15) among the branch mutations (such as in ESCC10 and ESCC12; Fig. 3c,d and Supplementary  Fig. 5 ). Interpreting these temporal differences in mutational spectra within the same tumor will require further investigations, but the data indicate that various mutational processes might have important roles in subclonal diversification during the progression of ESCC.
ITH of DNA methylation in ESCC
As with other cancers, epigenetic abnormalities have been associated with the development and pathogenesis of ESCC [28] [29] [30] . To decipher ESCC ITH at the epigenetic level and its potential relationship with subclonal gene mutations, the global methylation levels of 14 M-WES-profiled tumor and normal tissue pairs from three ESCC cases (ESCC01, ESCC03 and ESCC05) were obtained using the Illumina HumanMethylation450 (HM450) BeadChip. We first identified CpG probes that showed significant differences in methylation between tumor regions and normal tissue samples from the same case (except for ESCC01, for which a matched normal tissue sample was not available) and then divided these differentially methylated probes into those with shared changes (consistent within all tumor regions from the same case) and those with private changes (present in one or more of the regions, but not all). We used the probes with private changes to infer tumor evolution and constructed phyloepigenetic trees for each case on the basis of the Euclidean pairwise distances between methylation profiles 31, 32 (Online Methods). Topological similarities were tested between the phyloepigenetic and phylogenetic trees for all three cases by determining Robinson-Foulds (RF) A r t i c l e s distance relative to unrooted trees 33 (Fig. 4a) . Notably, in accordance with a recent report on glioma 32 , the RF distances (zero for all three cases) suggest high concordance between the genetic and epigenetic tree topologies for all three cases (Online Methods). As the distinction of private versus shared methylation changes is dependent on the probe selection cutoff used, we further tested four different cutoffs and noted that the phyloepigenetic trees were robust to cutoff selection and showed highly similar topological structures for all cutoff values ( Supplementary Fig. 6 ). Moreover, to alleviate confounding effects resulting from contamination with non-tumor DNA, two different methods were applied to account for and mitigate the potential influence of immune cells (the major non-cancer cell 0.20 ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ACA  ACC  ACG  ACT  CCA  CCC  CCG  CCT  GCA  GCC  GCG  GCT  TCA  TCC  TCG  TCT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT  ATA  ATC  ATG  ATT  CTA  CTC  CTG  CTT  GTA  GTC  GTG  GTT  TTA  TTC  TTG  TTT   a  c   d   b   30  29   1  2  3  4  5  6  7  8  9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 component in these samples; Supplementary Fig. 7) ; again, similar results were observed for the trees when using uncorrected methylation values or the values obtained with either correction method (Online Methods and Supplementary Fig. 8 ). These findings suggest a possible relationship between genomic and epigenomic alterations during the clonal evolution of ESCC cells and are indicative of the presence of multiple epigenetically distinct, subclonal cell populations, as recently observed in prostate cancer 31 , glioma 32 We observed that a number of TSGs, including EPHA7 (refs. 34, 35) , PCDH10 (refs. 36, 37) and DOK1 (refs. 38, 39) , among others, were hypermethylated at their promoters within some but not all tumor regions from the same case, indicating that their expression might be differentially suppressed in different tumor regions. Notably, some TSGs were mutated and acquired promoter hypermethylation, such as ASXL1 and EPHA7. Interestingly, ASXL1 was subject to both truncal/clonal mutation and shared hypermethylation at its promoter, suggesting that this gene was disrupted early during both the genomic and epigenomic evolutionary processes.
To explore the potential biological relevance of ITH for DNA methylation in ESCC, we next sought to determine whether the differentially methylated CpG loci in each case were enriched in particular functional genomic categories. We first divided the CpG probes into those where methylation was higher in the tumor than in adjacent normal tissues (hypermethylated) and those where methylation was lower (hypomethylated). Shared probes were selected for their relatively consistent changes in different tumor regions ( Supplementary  Fig. 9 ), whereas the remaining (private) probes exhibited prominent differences among the tumor regions ( Fig. 4b) and reflect the extensive ITH seen in the phyloepigenetic trees. We next compared shared and private probes by assigning them to various relevant functional genomic categories, including CpG islands (CGIs), CGI shores, promoters and enhancers, among others, and compared the frequencies of the probes in each category to the background frequencies, determined from all probes on the array (Fig. 4c) . As expected, shared CpG sites showed several methylation patterns commonly seen across cancer types 40, 41 , including strong enrichment of hypermethylated probes in CGI promoter regions and depletion of these probes in both long-range partially methylated domains (PMDs) and enhancer 0  5  10  15  20  25  30   T1   T2   T4   T2   T1   T4   T2   T3  T3   T4   T1   T3   N   N  N   T1  T2  T4  T3  T1   T2  T4  T3   T1  T2   T4  T3   ESCC05 ESCC03   Normal   Normal  T1 T2 T3 T4  T1  T2  T3  T4  Normal T1  T4  T2  T3  Normal T1  T2  T4  T3  Normal T2  T1  T3  T4 Fig. 9 ) are shown in green and gray shows the frequency for the entire set of probes on the array. The hypergeometric test (*P < 1 × 10 −5 ) was used to compare the frequency of each private and shared probe set category to that of array background (Online Methods). (d) Enriched GO Biological Processes for the genes associated with privately hypermethylated promoters in ESCC01 and ESCC03 (case ESCC05 was excluded because of the lack of sufficient privately hypermethylated promoters).
A r t i c l e s regions (after removing CGIs). Shared hypomethylated probes showed an inverse distribution: they were markedly depleted in CGI promoters, whereas they were enriched in PMDs as well as enhancer regions (Fig. 4c) . Strikingly, the distribution of private CpG sites for the most part resembled that of their shared counterparts (Fig. 4c) . In light of the known contribution of tumor-specific methylation to cancer biology 42, 43 , our results suggest that intratumoral methylation heterogeneity might have a role in the subclonal diversification of ESCC tumors. In support of this view, Gene Ontology (GO) analysis of the genes with private hypermethylated probes in their promoters showed that they were significantly enriched in cancer-related processes, including cell proliferation, differentiation, migration, adhesion and transcriptional regulation (Fig. 4d) . In addition, we noticed that private hypermethylated probes were even more enriched in CGI shores than shared hypermethylated probes (Fig. 4c) . Given previous observations that (i) cancer-specific differentially methylated regions occur more frequently within CGI shores than within CGIs 44, 45 and (ii) CGI shore methylation correlates with the expression of associated genes 44 , our observations further suggest the potential involvement of heterogeneity of DNA methylation in the evolutionary biology of ESCC cells.
DISCUSSION
ESCC is one of the most common malignancies, with relatively low overall 5-year survival rates. The main cause leading to unfavorable prognosis of patients with ESCC is the lack of effective therapies. Currently, none of the targeted therapies has been established for clinical management of ESCC 46 . Hundreds of genomic alterations, including somatic mutations and CNAs, have recently been identified in ESCC [4] [5] [6] [7] [8] [9] , but these data have not been translated into clinical applications. In addition, the genomic and epigenomic ITH and clonal evolution of ESCC tumors have not yet been characterized. In light of the evidence that ITH is the major cause of drug resistance and treatment failure 47 , deciphering the genomic diversity and clonal evolution of ESCC tumors will provide both a theoretical and translational basis for identifying new targets and designing personalized medicine strategies.
In the present study, the genomic ITH of 13 ESCC cases, as well as the epigenetic ITH of 3 of these individuals, were investigated through a variety of molecular approaches, and concordant tumor evolutionary trajectories were found as inferred from both DNA mutations and methylation. A very recent study of two ESCC cases reported that the ITH rate for somatic mutations was approximately 90% (ref. 48 ), whereas the rates in our study were much lower, with an average of 35.8%. The discrepancy may well be due to differences in sequencing depth between the two studies (50× versus 150×). Although the true extent of ITH is difficult to define, high sequencing coverage in our study offers improved resolution to decipher the spatial heterogeneity and clonal evolution of ESCC.
Although phylogeny analysis based on M-WES is not able to completely resolve the true temporal ordering of all somatic variants, we calculated that an average of 93.5% (range of 87.8 to 97.7%) of somatic mutations were compatible with the present phylogenic trees (Supplementary Fig. 1 ). For example, in case ESCC13, 282 of 294 variants (95.9%) were compatible with the evolution model based on the topological structure of the phylogenetic tree, and only 12 mutations, including ones in PIK3CA, were incompatible with the phylogenetic tree ( Supplementary Table 6 ). Therefore, the phylogeny method correctly resolves the temporal order of the vast majority of somatic mutations. Moreover, the evolutionary models inferred from the M-WES-based phylogeny are strongly supported by our DNA methylation phylogeny in all three cases (Fig. 4a) . Hence, this reconstruction of the phylogenetic topologies, from a completely independent molecular event, strongly reinforces the validity of these evolutionary models.
Resolving the clonal status of driver mutations will help to distinguish early from late events, and targeting clonally dominant driver mutations (early events) conceivably represents an optimized therapeutic strategy 10, 49 . In this study, despite driver mutations having a tendency to be truncal/clonal in comparison with passenger mutations, approximate 40% of driver mutations were branched or subclonal. This observation suggests that these driver mutations were relatively late events during tumor evolution and contributed to the emergence of distinct subclonal expansions after the founding clones were established. Notable examples included KIT, components of the PI3K-mTOR pathway (PIK3CA and MTOR) and components of the NFE2L2 pathway (NFE2L2 and KEAP1) . These examples, most of which are oncogenes, were frequently mutated as late events in ESCC. Furthermore, evidence of 'parallel evolution' was noted in some cases. For example, ESCC13 contained branch PIK3CA mutations derived in two spatially separated tumor regions, both harboring the p.Met1043Ile variant, which corresponds to a hotspot mutation. Similar parallel evolution was also observed in NFE2L2 mutations in ESCC12. Interestingly, PIK3CA, KIT and NFE2L2 mutations were fully clonal in some tumor regions but were completely absent in others, giving an illusion of clonal dominance. In addition, the number of within-patient mutations was higher than the number of within-region mutations. These results strongly suggest that the prevalence of these driver events and the rate of subclonality overall are likely underestimated when using a single biopsy to represent an individual patient.
Although alterations in DNA methylation in ESCC have been profiled using single-sampling approaches, their intratumoral diversity and the relationship to genetic lesions remain unknown. In the present study, we found a number of TSGs with private hypermethylation at the promoters, some of which have been associated with either tumorigenesis or progression of other cancer types, such as EPHA7 (refs. 34, 50) , ABCB4 (ref. 51) , PCDH10 (refs. 52,53) and DOK1 (refs. 38,39) . This finding suggests that these genes might be differentially inactivated in different tumor regions from the same individuals. We found profound epigenetic ITH in ESCC through global methylation analysis. Notably, subclonal evolutions inferred from DNA methylation closely recapitulated phylogenetic trees, indicating a possible relationship between genetic and epigenetic alterations in ESCC. Therefore, integrative analysis of both phylogenetic and phyloepigenetic trees may generate an enhanced understanding of clonal architecture, and identify the basis for subclonal epigenetic driver events. These features of epigenetic and genetic ITH shown by our study may have important implications in ESCC biology.
URLs. BWA-MEM, http://arxiv.org/abs/1303.3997v2; fpFilter Perl script, https://github.com/ckandoth/variant-filter; Bam-readcount, https://github.com/genome/bam-readcount; PHYLIP, http:// evolution.genetics.washington.edu/phylip.html.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. Digital sequencing and HM450 BeadChip files have been deposited in the Sequence Read Archive (SRA) under SRP072112 and the Gene Expression Omnibus (GEO) under GSE79366, respectively.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Patients and specimens. Tissue samples from 13 patients with ESCC, including primary esophageal tumors and matched morphologically normal esophageal epithelial margins, were collected at the Linzhou Esophagus Cancer Hospital, Henan province, China. All the samples used in this study were residual specimens collected after diagnosis sampling. All patients received no treatment before surgery and signed separate informed consent forms for sampling and molecular analyses. We also considered clinicopathological parameters when selecting these patients with ESCC, including sex, pathological tumor (pT) stage, regional lymph node metastasis and tumor differentiation, to avoid bias toward particular pathological characteristics (Supplementary Table 1) . Specifically, the male/female ratio in the current cohort was similar to that reported in the latest publication 54 . The number of patients with relatively early (pT1b or pT2) and late (pT3) tumor stage was five and eight, respectively. The status of lymph node metastasis (negative, n = 4; positive, n = 9), as well as tumor differentiation (G1, n = 1; G2, n = 6; G2/3, n = 2; G3, n = 4), was also taken into account. This study has been approved by the ethics committee or institutional review board of the Cancer Hospital/Institute, Peking Union Medical College and the Chinese Academy of Medical Sciences (approval NCC2013-066). The collection and publication of Chinese human genetic data used in the present study has been approved by the Ministry of Science and Technology. In 12 of 13 cases, four spatially separated tumor specimens were obtained from each individual, with each section at least 0.5 cm away from the others. In the case of ESCC04, three tumor regions were sampled. We carefully reviewed the hematoxylin and eosin slides for each tumor region before subjecting them to whole-exome sequencing analysis, to make sure that the tumor cell contents of the selected regions were comparable and were at least greater than 60% (representative hematoxylin and eosin images are provided in Supplementary Fig. 10 ).
Multiregional whole-exome sequencing. For each individual, genomic DNA of cells from different tumor regions and one matched normal epithelial tissue sample at the surgical margins was sequenced. Genomic DNA was extracted using the Qiagen DNeasy Blood and Tissue kit according to the manufacturer's instructions. For cases ESCC01 and ESCC02, whole-exome capture of genomic DNA was performed by BGI, using the BGI Exome Enrichment kit, and massively parallel sequencing of captured genomic DNA was performed and results were analyzed by BGI using the Complete Genomics platform. For the 11 other cases, the Agilent SureSelect Human All Exon v4 (51 Mb) kit was used for whole-exome capture of genomic DNA, and the captured DNA was sequenced by BGI using the Illumina HiSeq 4000 sequencing platform, with 150-bp paired-end sequencing.
Alignment of sequencing reads and somatic variant detection. 150-bp paired-end fastq files were aligned to the human reference genome (build hg19) using the BWA-MEM aligner in default mode (see URLs). Alignments were then filtered for duplicate reads using Samblaster 55 , and BAM files were indel realigned and base quality scores were recalibrated according to GATK best practices 56 .
Somatic variants were detected using VarScan2 (ref. 57 ). Tumor and matched normal pileup files were generated using the SAMtools 'mpileup' command and fed into the VarScan 'somatic' command 58 . Reference genome positions covered by at least 10 reads in the normal sample and 14 reads in tumor samples were considered for variant calling. Variants with VAF less than 0.07 were discarded. Raw somatic variants were filtered using the VarScan 'processSomatic' command with arguments --min-tumor-freq 0.07, --maxnormal-freq 0.02 and --p-value set to 0.05. The resulting high-quality somatic variants were filtered for false positives using the fpFilter Perl script (see URLs). The filtered variants were annotated with ANNOVAR 59 and filtered against the dbSNP135 database for commonly occurring SNPs 59 . Diseaseassociated variants annotated in the ClinVar database and the COSMIC database were retained.
Phylogenetic tree construction. For mutations that were detected from at least one tumor region, a method described by Stachler et al. 60 was used to increase the sensitivity of detecting these mutations in other tumor regions from the same individual with low VAF. In brief, Bam-readcount (see URLs) was used to obtain read counts for unique somatic variants across all tumor regions. A variant was considered to be absent if either its VAF was less than 0.02 or there were fewer than three reads. The VAFs across all the tumor regions for each individual were then used to generate a binary table. Phylogenetic trees were constructed on the basis of the binary tables using Discrete Character Parsimony, implemented in the PHYLogeny Inference Package (see URLs), with the matched morphologically normal epithelial margins as outgroup roots. On the basis of calculated branch/trunk lengths inferred from mutation counts, final trees were drawn manually.
Cancer cell fraction analysis. Copy number analysis from whole-exome sequencing data was performed using ReCapSeg, which is implemented as part of GATK (v4). Briefly, read counts for each of the exome targets were extracted from all samples and were divided by the total number of reads to generate proportional coverage. A panel of normal controls 14 was created using proportional coverage from all of the normal samples. Each of the tumor samples was compared to a panel of normal controls (PoN), followed by tangent normalization. The normalized coverage profiles were then segmented using circular binary segmentation 61 . Variants on the sex chromosomes (X and Y) were excluded from this analysis.
Tumor cellularity was determined on the basis of VAF and segmented copy number data using ABSOLUTE 62 , to determine the CCF of each mutation, as was previously described by McGranahan et al. 13 . Clonal status was defined according to the confidence interval of CCF. Mutations were classified as subclonal if the upper bound of their 95% confidence interval was less than 1.
Identification of putative driver mutations. We first identified putative cancer driver genes on the basis of recent large-scale ESCC sequencing data [4] [5] [6] [7] [8] , the COSMIC cancer gene census (August 2015) 11 and pan-cancer analysis 12 . Next, non-silent variants in these genes were evaluated, and putative driver mutations were identified if they met one of the following requirements: (i) either the exact mutation, the same mutation site or at least three mutations located within 15 bp of the variant were found in COSMIC and (ii) if the candidate gene was marked as recessive in COSMIC and the variant was predicted to be deleterious, including stop-gain, frameshift and splicing mutation, and had a SIFT score <0.05 (ref. 63) or a PolyPhen score >0.995 (refs. 64,65) .
Mutational signature analysis. Both silent and non-silent somatic mutations were classified as either truncal or branch as described earlier, and the mutational signatures of these variants were generated separately. We performed a multiple regression approach, deconstructSigs 26 , to extract signatures based on the Wellcome Trust Sanger Institute Mutational Signature Framework 27 and to statistically quantify the contribution of each signature for each tumor.
DNA methylation analysis and construction of phyloepigenetic trees.
The DNA methylation profiles of 12 tumor regions and 2 matched normal esophageal epithelial tissue samples from 3 ESCC cases examined by M-WES (ESCC01, ESCC03 and ESCC05) were generated using the Illumina Infinium HumanMethylation450 platform at the University of Southern California Norris Comprehensive Cancer Center Genomics Core. We performed basic data processing of the HM450 data using many of the same processing steps that we performed previously for The Cancer Genome Atlas (TCGA) data analysis, which is based on the Methylumi R package 66 with several additional quality control steps. Probes with detection P values greater than 0.01 in any of the samples were removed, as were probes overlapping with dbSNP SNPs and probes on the X or Y chromosome.
For intratumoral analysis, we defined a probe as private if the difference in β values for any single pair of tumor regions was at least 0.3; we defined a probe as shared if the differences in β values for all pairs of tumor regions were less than 0.1. Only private probes were used for construction of phyloepigenetic trees. For each tumor, pairwise Euclidean distances were calculated between all tumor regions using the complete set of private probes.
Phyloepigenetic trees were constructed from these pairwise distances, using the minimal evolution method implemented by the fastme.bal function in the R package ape 67 . Different probe selection cutoffs for calling private and shared probes produced similar results, with only minimal changes in cases ESCC01 (at the cutoff of 0.5) and ESCC05 (at the cutoff of 0.2; Supplementary Fig. 6 ).
Topological comparison for phylogenetic versus phyloepigenetic trees and other tree pairs was performed using the RF.dist function in the CRAN R package phangorn. Comparison in case ESCC01 was carried out on the basis of only tumor samples because of the lack of a matched normal sample in DNA methylation data (for visualization in Fig. 4a , we used normal samples from the other two cases as the root).
To mitigate the confounding effects of non-cancer cells in phyloepigenetic tree reconstruction, we performed additional bioinformatic analyses, as follows.
The major source of nonmalignant DNA contamination in esophageal tumors is immune cells 68 ; this has been shown by TCGA to be the case for most solid tumors 62, 69 . We confirmed this by review of all of our methylationprofiled samples through immunostaining of the leukocyte common antigen (LCA)/CD45 (representative immunohistochemistry images are shown in Supplementary Fig. 7) , which is a common marker of immune cells and is widely used in distinguishing infiltration of immune cells [70] [71] [72] [73] . To precisely determine the extent of immune cell contamination, we estimated the fraction of leukocytes in each sample using profiles of immune-specific methylation probes 74 , as described previously 62, 69 . Using this method, we noted that case ESCC01 was highly pure (estimated immune cell fraction = 7.1%, ranging from 1 to 14% in various tumor regions) and cases ESCC03 and ESCC05 contained an average of 20% and 32% immune cells, respectively (Supplementary Table 7 ).
We recalculated each phyloepigenetic tree using one of two methods to model the mixture of cancer and immune cells within the samples.
(1) As demonstrated in several TCGA marker papers, performing analysis using only the subset of Infinium probes unmethylated in purified leukocytes and dichotomizing/binarizing the tumor β value for these probes with a minimum β-value cutoff could minimize the influence of contaminating leukocytes [75] [76] [77] . We used HM450 profiles from purified leukocyte populations 74 and selected probes with a maximum β value less than 0.3 across all leukocyte samples. We then binarized the tumor β values as 1 if they were >0.3 and 0 otherwise. We computed pairwise distances between binarized values using the Jaccard index (dist function in R) and performed tree construction using these pairwise distances. The resulting trees are labeled "dichotomized" in Supplementary Figure 8 .
(2) In an independent approach, we modeled tumor β value as a linear combination of DNA from a mixture of cancer cells and leukocytes. The mixing ratio was estimated for each sample on the basis of methylation of leukocytespecific probes, as described above and previously 62, 69 . For each probe, we used the fixed mixing ratio, the average β value of the probe in purified leukocytes 74 and our measured β value in the tumor to estimate the methylation β value of the cancer cells alone. This method was used to reconstruct phyloepigenetic trees for each case, and the resulting trees are labeled "immune cell adjusted" in Supplementary Figure 8 .
Trees for both methods 1 and 2 were compared to the original trees using the RF method; RF values are listed in Supplementary Figure 8 .
Determining the genomic context of shared versus private methylation patterns. Shared versus private probes were identified on the basis of heterogeneity between different tumor regions. The groups were further divided into 'hypermethylated' and 'hypomethylated' probes, on the basis of comparisons of methylation in tumor samples and adjacent normal tissue. For hypermethylated probes from a specific case, we selected all probes with a methylation β value <0.3 in the adjacent normal sample (or a maximum β value of two other normal samples <0.3 for ESCC01) and a mean β value across all tumor regions that was at least 0.3 higher than the mean of normal sample(s). Similarly, for hypomethylated probes, we selected probes with ≥0.6 in the normal sample and at least 0.3 higher in the tumor than the mean of normal samples. For ESCC01, with no matched normal sample, we averaged the β values from the other two normal samples. Hyper-and hypomethylated probe sets are shown in Figure 4b-d and Supplementary Figure 9 . For the enrichment analysis in Figure 4c , promoters were defined as 1.5-kb regions up-and downstream of the RefSeq transcription start site, CGIs were taken from the HMM-defined set 78 , and CGI shores and enhancers were defined using the standard Illumina 450K annotation manifest. PMDs were called using the Roadmap 79 normal esophagus sample (E079), using an HMM-based segmentation method 80 . Enrichment/depletion P values for the enrichment of private versus shared probes in each genomic context were computed on the basis of a hypergeometric test, where null model frequencies were calculated on the basis of all probes present on the array (shown as "background" in Fig. 4c ).
Immunohistochemistry. Formalin-fixed and paraffin-embedded tissue slides were deparaffinized using xylene, rehydrated using xylene and ethanol, and then immersed in 3% hydrogen peroxide solution for 10 min, heated in citrate at 95 °C for 25 min and cooled at room temperature for 60 min. Slides were incubated overnight at 4 °C with antibody to LCA/CD45 (Cell Marque, 145M-96; diluted 1:100) and visualized using the PV-9000 Polymer Detection System following the manufacturer's instructions (Beijing Zhongshan Golden Bridge Biotechnology). Counterstaining was carried out with hematoxylin.
